Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Breast cancer (BC) is a common cancer all over the world that affects women. BC is one of
the leading causes of cancer mortality in women, which today has decreased with the …

Summary Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast
cancer; however, drug resistance is frequently encountered and poorly understood. We …

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …